The ALS Association Research Program
The Leader in Global ALS Research
The ALS Association has committed more than $67 million to find effective treatments and a cure for Lou Gehrig’s Disease. Our global research effort has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS.
The ALS Association has funded significant research milestones in the fight against ALS, including:
- The groundbreaking discovery of a genetic abnormality that is, to date, the most common cause known of ALS and FTD.
- The recent exciting finding involved in familial ALS shows how two proteins work together to buttress the survival of motor neurons.
- Discovery of the ALS gene, SOD1, responsible for 20 percent of all inherited ALS cases.
- Discovery of ALS6 in 2009, a new gene responsible for about 5% of all inherited ALS cases.
- The first clinical trial of ISIS-SOD1, a new drug that specifically targets the SOD1 gene.
Latest News
Discovery and Validation of Biomarkers in ALS
January 20, 2012A clinical study to collect biofluid samples for the banking and usage in ALS research.
2012 Research Awards
January 18, 2012The Association is pleased to announce a number of new grants focused on identifying new genes linked to the disease, the identification of biomarkers for ALS, and more.
November 2011 "Ask the Experts" Forum from Sydney, Australia Available Online
December 20, 2011Watch this Question and Answer session that took place on November 28 at the International Symposium on ALS/MND.
Olesoxime Phase III Trial Results Disappointing
December 13, 2011Phase III study did not demonstrate a significant increase in survival versus placebo in 512 patients with ALS.
For more information, please contact:
Bruijn-Yard Consultants, Medical Research
Lucie Bruijn, PhD
Chief Scientist
lucie@alsa-national.org
Tel: +1 727 412 0234
Fax: +1 727 499 9578
Mark Yard
Research Programs & Operations
mark@alsa-national.org
Tel: +1 203 641 1158
Fax: +1 727 499 9578
All written communications should be sent via e-mail, as an attachment to an e-mail or faxed.





